VXRT - Vaxart up 10% on quarterly revenue beat eyes COVID oral vaccine trial start in Q2 May, 13 2024 05:01 PM Vaxart Inc. 2024-05-13 17:01:34 ET More on Vaxart Vaxart, Inc. (VXRT) Q4 2023 Earnings Call Transcript Vaxart GAAP EPS of -$0.14 in-line, revenue of $2.18M beats by $1.38M Vaxart FY 2023 Earnings Preview Seeking Alpha’s Quant Rating on Vaxart Historical earnings data for Vaxart For further details see: Vaxart up 10% on quarterly revenue beat, eyes COVID oral vaccine trial start in Q2